Tag Archives: Cell Therapeutics
Five Most Attractive Stocks in Healthcare Sector: Cell Therapeutics, Star Scientific, CEL-SCI, Alkermes, Ironwood Pharmaceuticals
Cell Therapeutics Inc (NASDAQ:CTIC) was present at the UBS Global Healthcare Conference in New York, NY. The program was scheduled to start at 2:30 PM ET May 21, 2013.
Cell Therapeutics Inc (NASDAQ:CTIC) last session’s volume of 878,275 shares was …
Healthcare Sector Snapshot: Unilife, Affymax, Cell Therapeutics, Ariad, Warner
Unilife Corp’s (NASDAQ:UNIS) stock hiked 14.20% or +0.49 cent to settle at $3.94 on Tuesday.
Unilife Corp (NASDAQ:UNIS) last session’s volume of 4.45 million shares was higher than its average volume of 1.61 million shares. The stock after opening at …
Humana Inc.’s (NYSE:HUM) Profit Slips on Inflated Coverage Costs – HUM, LLY, ANTH, RMTI, CTIC, ARNA, LLY,
Humana Inc.’s (NYSE:HUM) fourth-quarter earnings plunged down 3.5% as inflated coverage costs covered the health-care firm’s revenue growth from hiked membership. Past month, Humana finished its approximately $850 million takeover of Metropolitan Health Networks Inc., a medical-services supplier mainly operating …
WellPoint Inc. (NYSE:WLP) Lifts Up Earnings Outlook for 2013 – WLP, AET, CI, CTIC, PFE, BSX, PPHM, ABBV, DNDN
WellPoint Inc. (NYSE:WLP) predicted earnings for this year to be close to the high end or minimally over its previous expectations.
The health-benefits provider had formerly reported that it predicts net income for the year around $7.30 to $7.40 a …
UnitedHealth (NYSE:UNH) 2013 Profit Forecasts Misses Wall Street Estimates – UNH, AET, HUM, BSX, SRPT, CTIC, PFE, ARNA, JNJ
UnitedHealth Group Inc (NYSE:UNH), the biggest United States private health insurer, reported on Monday that it projected earnings in the range of $5.25 to $5.50 a share in 2013, lower than analysts’ forecasts.
The company reported that revenue should be …
GlaxoSmithKline (NYSE:GSK) Plans to Buy Additional Stock in Indian Unit – GSK, MRK, NVS, SRPT, CTIC, SQNM, ESRX, STJ, GILD
GlaxoSmithKline PLC (NYSE:GSK)has shown interest in purchasing a further stake of almost 31.8% in its Indian division, GlaxoSmithKline Consumer Healthcare Ltd. , at 3,900 rupees ($70.3) a share, the UK-located firm stated in a report on Monday.
The proposal is …
